PCDH1 Binding Agents Block Hantavirus Entry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hantavirus infections, such as hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS), lack effective vaccines and therapeutics, leading to high mortality rates and limited supportive care options.
Innovation Solution
Administering agents that bind to or inhibit protocadherin-1 (PCDH1), a protein critical for hantavirus entry into cells, to prevent or treat hantavirus infections, including the use of antibodies, aptamers, small molecules, or RNA interference molecules that target PCDH1.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If supportive care is provided for hantavirus infections, then patient survival is maintained through basic medical support, but mortality rates remain high at 60% for HPS and 12% for HFRS
Solution Approach 1:
The patent applies preliminary action by administering agents that block hantavirus entry into cells before the virus can establish infection and cause disease. This preventive approach targets the initial viral entry step, preventing the cascade of pathological events that lead to high mortality, rather than treating symptoms after infection is established.
Solution Approach 2:
The patent uses intermediary molecules (such as antibodies, aptamers, or small molecules) that bind to cellular receptors or viral components to prevent hantavirus entry. These intermediary agents act as blockers that interfere with the virus-receptor interaction, thereby preventing infection without requiring the immune system to respond to an established infection.
2Ease of operation
If no specific therapeutics are used for hantavirus infections, then treatment simplicity is maintained through supportive care only, but effective treatment is lacking resulting in high mortality
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism of hantavirus entry into cells. By identifying and blocking the receptor-virus interaction step, the treatment isolates and intervenes at the critical entry point, providing a targeted therapeutic approach that maintains operational simplicity while dramatically improving effectiveness.
3Reliability
If protocadherin-1 binding agents are administered to block viral entry, then hantavirus infection is prevented or treated with high efficacy, but the complexity of treatment increases from supportive care to targeted molecular therapy
Solution Approach 1:
The patent employs agents that naturally bind to protocadherin-1 or other cellular receptors to block hantavirus entry. These molecules leverage existing biological recognition mechanisms, allowing the treatment to function through natural molecular interactions rather than requiring complex delivery systems or activation mechanisms, thereby reducing operational complexity despite the targeted approach.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively reduces or prevents hantavirus infection by blocking viral entry into cells, offering a potential therapeutic target for treating HPS and HFRS, with specific efficacy against New World hantaviruses like Andes and Sin Nombre viruses.
Implementation Method 1
administering agents that bind to or inhibit protocadherin-1 (PCDH1), a protein critical for hantavirus entry into cells
Implementation Method 2
the use of antibodies, aptamers, small molecules, or RNA interference molecules that target PCDH1
Data Source
AI summary
Methods and assays are disclosed for treating a subject with a hantavirus infection using an agent that binds to protocadherin-1 (PCDH1) or inhibits expression of protocadherin-1 (PCDH1).